Shin J. Oh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shin J. Oh has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Yuki Hatanaka
Department of Neurology, Teikyo University School of Medicine, Tokyo, Japan
10 shared publicationsGwen C. Claussen
Department of Neurology, The University of Alabama at Birmingham, UAB Station, Birmingham, Alabama 35294, USA
8 shared publicationsGwendolyn C. Claussen
Department of Neurology, University of Alabama at Birmingham, UAB Station, Birmingham, Alabama, 35294, USA
6 shared publicationsLiang Lu
Department of Neurology, University of Alabama at Birmingham, UAB Station, Birmingham, Alabama, 35294, USA
6 shared publicationsShoji Hemmi
Department of Neurology, Kawasaki Medical School, Kurashiki, Okayama, Japan
6 shared publicationsMarla B. Morgan
Department of Neurology, University of Alabama at Birmingham, Veterans Affairs Medical Center, Birmingham, AL
5 shared publications
Latest Publications
- 28 July 2024
- Published by Wiley in Muscle & Nerve
- Vol. 70 (4) , 731-732
Myasthenia gravis Lambert–Eaton overlap syndrome: Recommended modification for the diagnostic criteria
In 2016, MLOS (myasthenia gravis Lambert–Eaton overlap syndrome) was coined to represent an entity of overlap syndrome of myasthenia gravis and Lambert–Eaton myasthenic syndrome. Fifty‐five MLOS patients have been identified. Modification of the diagnostic criteria for MG by adding MuSK positive antibody testing is recommended. Two MuSK positive MLOS patients were identified by the new diagnostic criteria.
- 28 July 2024
- Published by Wiley in Muscle & Nerve
- Vol. 70 (4) , 731-732
Myasthenia gravis Lambert–Eaton overlap syndrome: Recommended modification for the diagnostic criteria
In 2016, MLOS (myasthenia gravis Lambert–Eaton overlap syndrome) was coined to represent an entity of overlap syndrome of myasthenia gravis and Lambert–Eaton myasthenic syndrome. Fifty‐five MLOS patients have been identified. Modification of the diagnostic criteria for MG by adding MuSK positive antibody testing is recommended. Two MuSK positive MLOS patients were identified by the new diagnostic criteria.
- 1 March 2024
- Published by Wolters Kluwer Health in Journal of Clinical Neuromuscular Disease
- Vol. 25 (3) , 163-170
Nodal Conduction Block and Internodal Conduction Block in Nodopathy
Objectives: In 2015, a new term “nodopathy” was introduced to represent a group of neuropathy because of autoantibodies at the node of Ranvier and paranodal area. This review was conducted to highlight the electrophysiologic characteristics of acute and chronic nodopathies by the newly introduced term: “nodal conduction block (CB); CB without temporal dispersion or slow nerve conduction velocity” and by introducing a new term: “internodal CB; CB with temporal dispersion or/and slow nerve conduction velocity”. Methods: Through PubMed searches, 23 cases of acute (4 weeks of neuropathy) nodopathy are identified. Two other required inclusion criteria are positive nodal antibody test and detailed nerve conduction data with or without figure. All existing data were analyzed to see whether these cases had nodal or internodal CB. Results: Among 23 cases of acute nodopathy, 11 had nodal CB, 9 internodal CB, and 3 mixed CB. Thus, nodal CB was observed in 61% of acute nodopathy cases and internodal CB in 52% of acute nodopathy cases. Among 12 cases of chronic nodopathy, all 12 had internodal CB. Conclusions: Nodal CB is the nerve conduction characteristic of acute nodopathy, but internodal CB does not rule out acute nodopathy. Internodal CB is the nerve conduction characteristic of chronic nodopathy.
- 1 March 2024
- Published by Wolters Kluwer Health in Journal of Clinical Neuromuscular Disease
- Vol. 25 (3) , 163-170
Nodal Conduction Block and Internodal Conduction Block in Nodopathy
Objectives: In 2015, a new term “nodopathy” was introduced to represent a group of neuropathy because of autoantibodies at the node of Ranvier and paranodal area. This review was conducted to highlight the electrophysiologic characteristics of acute and chronic nodopathies by the newly introduced term: “nodal conduction block (CB); CB without temporal dispersion or slow nerve conduction velocity” and by introducing a new term: “internodal CB; CB with temporal dispersion or/and slow nerve conduction velocity”. Methods: Through PubMed searches, 23 cases of acute (4 weeks of neuropathy) nodopathy are identified. Two other required inclusion criteria are positive nodal antibody test and detailed nerve conduction data with or without figure. All existing data were analyzed to see whether these cases had nodal or internodal CB. Results: Among 23 cases of acute nodopathy, 11 had nodal CB, 9 internodal CB, and 3 mixed CB. Thus, nodal CB was observed in 61% of acute nodopathy cases and internodal CB in 52% of acute nodopathy cases. Among 12 cases of chronic nodopathy, all 12 had internodal CB. Conclusions: Nodal CB is the nerve conduction characteristic of acute nodopathy, but internodal CB does not rule out acute nodopathy. Internodal CB is the nerve conduction characteristic of chronic nodopathy.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Clinical Neurology
- Vol. 20 (4) , 353-361
Amifampridines are the Most Effective Drugs for Treating Lambert-Eaton Myasthenic Syndrome With a Focus on Pediatric Lambert-Eaton Myasthenic Syndrome
Oh SJ. J Clin Neurol. 2024 Jun;20:e54. https://doi.org/10.3988/jcn.2024.0018
- 1 January 2024
- Published by XMLink in Journal of Clinical Neurology
- Vol. 20 (4) , 353-361
Open AccessAmifampridines are the Most Effective Drugs for Treating Lambert-Eaton Myasthenic Syndrome With a Focus on Pediatric Lambert-Eaton Myasthenic Syndrome
Oh SJ. J Clin Neurol. 2024 Jun;20:e54. https://doi.org/10.3988/jcn.2024.0018
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Clinical Neurology
- Vol. 20 (3) , 276-284
Sensory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Neglected Immunotherapy-Responsive Sensory Neuropathy
Background and Purpose To report an improvement with immunotherapy in 34 (85%)/40 patients who required an immunotherapy among 56 patients with sensory chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods Sensory CIDP was diagnosed when two inclusion criteria are met: 1) acquired, chronic progressive or relapsing symmetrical or asymmetrical sensory polyneuropathy that had progressed for >2 months; and 2) definite electrophysiological and/or biopsy evidence of demyelinating neuropathy. Results Fifty-six patients with sensory CIDP were identified. Evidence of demyelination was obtained from by the routine motor nerve conduction study (NCS) in 39 (70%) patients, from a nerve biopsy in 10, and from a near-nerve needle sensory NCS in 7 patients. The most prominent laboratory abnormality was a high protein level in the cerebrospinal fluid in 21 (49%) of 43 tested patients. Immunotherapy was required in 41 (79%) of the 52 followed-up patients. An improvement with immunotherapy was observed in 36 (88%)/41 patients. In three patients, motor weakness developed in 5-8 years' follow-up period and so, their diagnosis was changed to CIDP. Conclusions Sensory CIDP is responded to an immunotherapy in 88% of the treated patients. Sensory CIDP was diagnosed by the routine motor NCS in 70% of patients and by a sural nerve biopsy in 18% of patients. Thus, sensory CIDP should be recognized as a treatable CIDP variant among the different types of "idiopathic sensory neuropathy."
- 1 January 2024
- Published by XMLink in Journal of Clinical Neurology
- Vol. 20 (3) , 276-284
Open AccessSensory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Neglected Immunotherapy-Responsive Sensory Neuropathy
Background and Purpose To report an improvement with immunotherapy in 34 (85%)/40 patients who required an immunotherapy among 56 patients with sensory chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods Sensory CIDP was diagnosed when two inclusion criteria are met: 1) acquired, chronic progressive or relapsing symmetrical or asymmetrical sensory polyneuropathy that had progressed for >2 months; and 2) definite electrophysiological and/or biopsy evidence of demyelinating neuropathy. Results Fifty-six patients with sensory CIDP were identified. Evidence of demyelination was obtained from by the routine motor nerve conduction study (NCS) in 39 (70%) patients, from a nerve biopsy in 10, and from a near-nerve needle sensory NCS in 7 patients. The most prominent laboratory abnormality was a high protein level in the cerebrospinal fluid in 21 (49%) of 43 tested patients. Immunotherapy was required in 41 (79%) of the 52 followed-up patients. An improvement with immunotherapy was observed in 36 (88%)/41 patients. In three patients, motor weakness developed in 5-8 years' follow-up period and so, their diagnosis was changed to CIDP. Conclusions Sensory CIDP is responded to an immunotherapy in 88% of the treated patients. Sensory CIDP was diagnosed by the routine motor NCS in 70% of patients and by a sural nerve biopsy in 18% of patients. Thus, sensory CIDP should be recognized as a treatable CIDP variant among the different types of "idiopathic sensory neuropathy."
- 9 February 2016
- Published by Wiley in Muscle & Nerve
- Vol. 53 (6) , 866-871
Diagnostic markers of axonal degeneration and demyelination in sensory nerve conduction
- 9 February 2016
- Published by Wiley in Muscle & Nerve
- Vol. 53 (6) , 866-871
Diagnostic markers of axonal degeneration and demyelination in sensory nerve conduction
- 6 February 2016
- Published by Wiley in Muscle & Nerve
- Vol. 53 (5) , 717-725
Amifampridine phosphate (Firdapse®) is effective and safe in a phase 3 clinical trial in LEMS
Objective: We evaluated the efficacy and safety of amifampridine phosphate (Firdapse®) for symptomatic treatment in Lambert‐Eaton myasthenic syndrome (LEMS).Methods: Phase 3, randomized, double‐blind, study. Patients were treated initially with amifampridine phosphate for 7–91 days, followed by randomization to continue amifampridine phosphate for 14 days or placebo (7‐day taper, 7‐day placebo). The primary efficacy endpoints were changes from baseline at day 14 in Quantitative Myasthenia Gravis and Subject Global Impression scores.Results: The coprimary efficacy end points and 1 of the secondary efficacy end points were met, showing a significant benefit of aminfampridine phosphate over placebo at Day 14. All 5 primary, secondary, and tertiary endpoints achieved statistical significance at Day 8. Amifampridine phosphate was well tolerated; the most common adverse events were oral and digital paresthesias, nausea, and headache.Conclusions: This study provides Class I evidence of efficacy of amifampridine phosphate as a symptomatic treatment for LEMS.Muscle Nerve53: 717–725, 2016
- 6 February 2016
- Published by Wiley in Muscle & Nerve
- Vol. 53 (5) , 717-725
Amifampridine phosphate (Firdapse®) is effective and safe in a phase 3 clinical trial in LEMS
Objective: We evaluated the efficacy and safety of amifampridine phosphate (Firdapse®) for symptomatic treatment in Lambert‐Eaton myasthenic syndrome (LEMS).Methods: Phase 3, randomized, double‐blind, study. Patients were treated initially with amifampridine phosphate for 7–91 days, followed by randomization to continue amifampridine phosphate for 14 days or placebo (7‐day taper, 7‐day placebo). The primary efficacy endpoints were changes from baseline at day 14 in Quantitative Myasthenia Gravis and Subject Global Impression scores.Results: The coprimary efficacy end points and 1 of the secondary efficacy end points were met, showing a significant benefit of aminfampridine phosphate over placebo at Day 14. All 5 primary, secondary, and tertiary endpoints achieved statistical significance at Day 8. Amifampridine phosphate was well tolerated; the most common adverse events were oral and digital paresthesias, nausea, and headache.Conclusions: This study provides Class I evidence of efficacy of amifampridine phosphate as a symptomatic treatment for LEMS.Muscle Nerve53: 717–725, 2016
- 26 November 2015
- Published by Wiley in Muscle & Nerve
- Vol. 53 (1) , 20-26
Myasthenia gravis Lambert‐Eaton overlap syndrome
Introduction: To assess whether a myasthenia gravis (MG) Lambert‐Eaton overlap syndrome (MLOS) exists. Methods: Case reports that met the universally accepted diagnostic criteria for MG and Lambert‐Eaton myasthenic syndrome (LEMS) were sought through a PubMed search. Fifty‐five possible cases of MLOS were identified. Results: Thirty‐nine cases met the diagnostic criteria for MG and LEMS. Analysis of clinical features showed that these patients have common MG and LEMS symptoms: oculo‐bulbar paresis and good response to anti‐cholinesterase for MG and limb weakness and decreased or absent reflexes for LEMS. All had the classical LEMS pattern in the repetitive nerve stimulation test: low compound muscle action potential amplitude and incremental response > 60% with brief exercise or at high rate of stimulation. Eight patients had combined positive acetylcholine receptor antibody (AChR‐ab) or muscle‐specific kinase‐ab and voltage‐gated calcium channel‐ ab tests. Conclusions: A myasthenia gravis Lambert‐Eaton overlap syndrome (MLOS) does exist. Muscle Nerve 53: 20–26, 2016
- 26 November 2015
- Published by Wiley in Muscle & Nerve
- Vol. 53 (1) , 20-26
Myasthenia gravis Lambert‐Eaton overlap syndrome
Introduction: To assess whether a myasthenia gravis (MG) Lambert‐Eaton overlap syndrome (MLOS) exists. Methods: Case reports that met the universally accepted diagnostic criteria for MG and Lambert‐Eaton myasthenic syndrome (LEMS) were sought through a PubMed search. Fifty‐five possible cases of MLOS were identified. Results: Thirty‐nine cases met the diagnostic criteria for MG and LEMS. Analysis of clinical features showed that these patients have common MG and LEMS symptoms: oculo‐bulbar paresis and good response to anti‐cholinesterase for MG and limb weakness and decreased or absent reflexes for LEMS. All had the classical LEMS pattern in the repetitive nerve stimulation test: low compound muscle action potential amplitude and incremental response > 60% with brief exercise or at high rate of stimulation. Eight patients had combined positive acetylcholine receptor antibody (AChR‐ab) or muscle‐specific kinase‐ab and voltage‐gated calcium channel‐ ab tests. Conclusions: A myasthenia gravis Lambert‐Eaton overlap syndrome (MLOS) does exist. Muscle Nerve 53: 20–26, 2016
- 29 October 2014
- Published by Wiley in Muscle & Nerve
- Vol. 52 (1) , 34-38
Asymptomatic vasculitic neuropathy
Introduction: We performed a retrospective analysis of the clinical, pathological, and electrophysiological features of 21 cases of Asymptomatic vasculitic neuropathy (AsVN). Methods: Among 270 patients with biopsy-proven vasculitic neuropathy, we identified 21 (7.8%) who had asymptomatic neuropathy. Results: Of the 21 patients with AsVN, 11 were women and 10 were men. Their mean age was 62.5 years. Referring physicians suspected systemic vasculitis on the basis of clinical and laboratory features, but none of the patients had neuropathy by examination. Screening nerve conduction studies identified neuropathy in all patients, leading us to perform a sural nerve biopsy, which confirmed the diagnosis of vasculitis. Twelve patients had active (type I), 6 had inactive (type II), and 3 had probable (type III) vasculitis. Vasculitis was primary in 10 patients and secondary in 11. Conclusions: Nerve conduction study is an important tool for identifying AsVN, a subtype of vasculitic neuropathy. Muscle Nerve 52: 34–38, 2015
- 29 October 2014
- Published by Wiley in Muscle & Nerve
- Vol. 52 (1) , 34-38
Asymptomatic vasculitic neuropathy
Introduction: We performed a retrospective analysis of the clinical, pathological, and electrophysiological features of 21 cases of Asymptomatic vasculitic neuropathy (AsVN). Methods: Among 270 patients with biopsy-proven vasculitic neuropathy, we identified 21 (7.8%) who had asymptomatic neuropathy. Results: Of the 21 patients with AsVN, 11 were women and 10 were men. Their mean age was 62.5 years. Referring physicians suspected systemic vasculitis on the basis of clinical and laboratory features, but none of the patients had neuropathy by examination. Screening nerve conduction studies identified neuropathy in all patients, leading us to perform a sural nerve biopsy, which confirmed the diagnosis of vasculitis. Twelve patients had active (type I), 6 had inactive (type II), and 3 had probable (type III) vasculitis. Vasculitis was primary in 10 patients and secondary in 11. Conclusions: Nerve conduction study is an important tool for identifying AsVN, a subtype of vasculitic neuropathy. Muscle Nerve 52: 34–38, 2015
- 1 February 2014
- Published by Elsevier in Clinical Neurophysiology
- Vol. 125 (2) , 411-414
Post-exercise exhaustion in Lambert–Eaton myasthenic syndrome
- 1 February 2014
- Published by Elsevier in Clinical Neurophysiology
- Vol. 125 (2) , 411-414
Post-exercise exhaustion in Lambert–Eaton myasthenic syndrome